TY - JOUR
T1 - Surgery for small cell lung cancer
T2 - A retrospective analysis of 243 patients from japanese lung cancer registry in 2004
AU - Takei, Hidefumi
AU - Kondo, Haruhiko
AU - Miyaoka, Etsuo
AU - Asamura, Hisao
AU - Yoshino, Ichiro
AU - Date, Hiroshi
AU - Okumura, Meinoshin
AU - Tada, Hirohito
AU - Fujii, Yoshitaka
AU - Nakanishi, Yoichi
AU - Eguchi, Kenji
AU - Dosaka-Akita, Hirotoshi
AU - Kobayashi, Hideo
AU - Sawabata, Noriyoshi
AU - Yokoi, Kohei
PY - 2014/8
Y1 - 2014/8
N2 - Introduction: Indications for surgical resection for small cell lung cancer (SCLC) have been very limited. Because early-stage SCLC is a rare presentation of lung cancer, studies comparing surgical resection among a large number of patients are unlikely to be conducted. This study reports the most recent surgical outcomes of a large number of SCLC patients who underwent surgery in 2004.Methods: In 2010, the Japanese Joint Committee of Lung Cancer Registry performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of 11,663 patients who underwent resection for primary lung cancer in 2004. Of the 11,663 patients, 243 patients with SCLC (2.1%) were included in this study. The registry data of the patients with SCLC were analyzed, and the clinicopathologic profiles and surgical outcomes of the patients were evaluated.Results: The 5-year survival rate for all cases (n = 243, 213 males, mean age 68.2 years) was 52.6%. The 5-year survival rates by c-stage and p-stage were as follows: IA, 64.3% (n = 132) and 72.3% (n = 93); IB, 45.7% (n = 36) and 61.1% (n = 51); IIA, 50.5% (n =25); and 44.8% (n = 27); IIB, 33.3% (n = 10) and 40.3% (n = 17); IIIA, 30.5% (n = 30) and 23.4% (n = 45); and IV, 0% (n = 7) and 0% (n = 9), respectively. A multivariate analysis showed that the significant prognostic factors were age, gender, c-stage, and surgical curability. A kappa value was moderate conformity between c-stage and p-stage in all cases.Conclusions: Surgical resection in selected patients with early-stage SCLC, especially stage I, had favorable results.
AB - Introduction: Indications for surgical resection for small cell lung cancer (SCLC) have been very limited. Because early-stage SCLC is a rare presentation of lung cancer, studies comparing surgical resection among a large number of patients are unlikely to be conducted. This study reports the most recent surgical outcomes of a large number of SCLC patients who underwent surgery in 2004.Methods: In 2010, the Japanese Joint Committee of Lung Cancer Registry performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of 11,663 patients who underwent resection for primary lung cancer in 2004. Of the 11,663 patients, 243 patients with SCLC (2.1%) were included in this study. The registry data of the patients with SCLC were analyzed, and the clinicopathologic profiles and surgical outcomes of the patients were evaluated.Results: The 5-year survival rate for all cases (n = 243, 213 males, mean age 68.2 years) was 52.6%. The 5-year survival rates by c-stage and p-stage were as follows: IA, 64.3% (n = 132) and 72.3% (n = 93); IB, 45.7% (n = 36) and 61.1% (n = 51); IIA, 50.5% (n =25); and 44.8% (n = 27); IIB, 33.3% (n = 10) and 40.3% (n = 17); IIIA, 30.5% (n = 30) and 23.4% (n = 45); and IV, 0% (n = 7) and 0% (n = 9), respectively. A multivariate analysis showed that the significant prognostic factors were age, gender, c-stage, and surgical curability. A kappa value was moderate conformity between c-stage and p-stage in all cases.Conclusions: Surgical resection in selected patients with early-stage SCLC, especially stage I, had favorable results.
UR - http://www.scopus.com/inward/record.url?scp=84905865315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905865315&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000226
DO - 10.1097/JTO.0000000000000226
M3 - Article
C2 - 25157766
AN - SCOPUS:84905865315
SN - 1556-0864
VL - 9
SP - 1140
EP - 1145
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 8
ER -